Search results
Results From The WOW.Com Content Network
Spironolactone is commonly used in the treatment of hirsutism in women, and is considered to be a first-line antiandrogen for this indication. [68] Spironolactone can be used in the treatment of female-pattern hair loss (pattern scalp hair loss in women). [ 69 ]
A woman with hirsutism from increased androgen exposure. Hyperandrogenism affects 5–10% of women of reproductive age. [11] Hyperandrogenism can affect both men and women but is more noticeable in women since elevated levels of androgens in women may facilitate virilization. Because hyperandrogenism is characterized by elevated male sex ...
In addition, contrarily to the case of men, flutamide has been found in various clinical studies to be more effective than CPA (and particularly spironolactone) in the treatment of androgen-dependent conditions such as acne and hirsutism in women.
Spironolactone has been found to be effective in the treatment of hirsutism in women at a dosage of as low as 50 mg/day. [60] At dosages of 100 mg/day and 200 mg/day, observed reductions in hair shaft diameter were 19% ± 8% and 30% ± 3%, respectively (p = 0.07).
1962: Spironolactone is first reported to produce gynecomastia in men [219] [221] 1966: Benorterone is the first known antiandrogen to be studied clinically, to treat acne and hirsutism in women [222] [223] 1963: The antiandrogenic activity of cyproterone acetate is discovered [48] [224]
Hirsutism is excessive body hair on parts of the body where hair is normally absent or minimal. The word is from early 17th century: from Latin hirsutus meaning "hairy". [ 2 ] It usually refers to a male pattern of hair growth in a female that may be a sign of a more serious medical condition, [ 3 ] especially if it develops well after puberty ...
Androgen-dependent skin and hair conditions like acne, hirsutism, [5] seborrhea, and pattern hair loss (androgenic alopecia) in women; Hyperandrogenism, such as due to polycystic ovary syndrome or congenital adrenal hyperplasia, in women; As a component of hormone therapy for transgender women [6] [7] Precocious puberty in boys
Canrenone is an active metabolite of spironolactone, canrenoic acid, and potassium canrenoate, and is considered to be partially responsible for their effects. [9] It has been found to have approximately 10 to 25% of the potassium-sparing diuretic effect of spironolactone, [ 16 ] whereas another metabolite, 7α-thiomethylspironolactone (7α-TMS ...